ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 618

BAFF/BLyS Gene Expression Predicts Disease Activity in Systemic Lupus Erythematosis Over One Year

Eric Zollars1, Hong Fang2, Jadwiga Bienkowska3, Norm Allaire3, Susan Kalled3 and Michelle Petri2, 1Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Biogen Idec Inc., Cambridge, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: BAFF and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: The search for a marker of SLE disease activity has included inflammatory markers, chemokines and gene signatures.  We explored the ability of the BAFF gene expression to predict SLE disease activity in the subsequent year after measurement.

Methods: 292 patients (59% Caucasian, 34% African-American, 92% female, mean age 46 ±12 years) were enrolled in a prospective observational study.  At baseline, BAFF gene expression level was determined in peripheral blood RNA using Affymetrix chips.  Clinical associations, based on the same-day visit disease activity (using the Physician Global Assessment and SELENA SLEDAI) as well as activity over the ensuing year were then determined.  Results were determined with a generalized estimating equation to account for the repeated observations among the same patients. 

Results: The number of visits within a year after the measurement of BAFF gene expression varied from 1-9.  Six patients had 1 visit, 46 patients had 2-3 visits, 159 patients had 4 visits, and 81 patients had more than 4 visits.

Table 1.Percentage of visits with disease activity by BAFF gene expression

 

Variable

Low BAFF (<10.7)

(%, N=387)

Med BAFF (10.7-11.4) (%, N=476)

High BAFF (>11.4)

(%, N=347)

P-value

Adjusted P-value for Race

Physician global assessment >1

8%

21%

24%

.0003

.0041

SLEDAI ≥2

36%

57%

71%

<.0001

<.0001

Urine Protein/Creatinine Ratio (≥0.5)

3%

13%

13%

.0004

.0096

Anti-dsDNA ≥ 10

9%

21%

35%

<.0001

<.0001

C3 <79 mg/dL

4%

11%

21%

.0002

.0004

C4 <12 mg/dL

4%

11%

19%

.0004

.0005

ESR >20

35%

55%

63%

<.0001

.0005

We controlled for race, sex, baseline low complement and baseline anti-dsDNA.

Table 2.Average disease activity over a year of follow-up.

 

Variable

BAFF gene expression

Unadjusted Activity

Adjusted Mean Differences

P-values

PGA

Low (<10.7)

0.48

0  (Ref. Group)

 

 

Med  (10.7-11.4)

0.70

0.14

.044

 

High  (>11.4)

0.74

0.15

.045

SLEDAI

Low (<10.7)

1.08

0 (Ref. Group)

 

 

Med (10.7-11.4)

2.10

0.39

.031

 

High (>11.4)

2.98

0.72

.0029

Conclusion: We have previously shown that the BAFF gene expression correlates with same-day disease activity.  We now can prove that BAFF gene expression predicts disease activity over the ensuing year. This supports BAFF/BLyS as a target for clinical intervention.


Disclosure:

E. Zollars,
None;

H. Fang,
None;

J. Bienkowska,

Biogen Idec,

3;

N. Allaire,

Biogen Idec,

3;

S. Kalled,

Biogen Idec,

3;

M. Petri,

HGS,

5,

GlaxoSmithKline,

5,

Medimmune,

5,

UCB,

5,

Anthera,

5,

Pfizer Inc,

5,

TEVA,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baffblys-gene-expression-predicts-disease-activity-in-systemic-lupus-erythematosis-over-one-year/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology